Verve Therapeutics (VERV) Earnings Date, Estimates & Call Transcripts → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free verv Stock Alerts $6.17 -0.41 (-6.23%) (As of 11:03 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 20EstimatedActual EPS (Feb. 27) -$0.69 Beat By $0.14 Consensus EPS (Feb. 27) -$0.83 Get Verve Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for VERV and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueVERV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VERV Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. Verve Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.79)($0.56)($0.68)Q2 20242($0.75)($0.60)($0.68)Q3 20242($0.81)($0.61)($0.71)Q4 20242($0.77)($0.62)($0.70)FY 20248($3.12)($2.39)($2.76)Q1 20251($0.82)($0.82)($0.82)Q2 20251($0.78)($0.78)($0.78)Q3 20251($0.83)($0.83)($0.83)VERV Earnings Date and InformationVerve Therapeutics last released its quarterly earnings results on February 27th, 2024. The reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.14. The firm had revenue of $5.14 million for the quarter, compared to the consensus estimate of $3.95 million. Verve Therapeutics has generated ($3.12) earnings per share over the last year (($3.12) diluted earnings per share). Earnings for Verve Therapeutics are expected to grow in the coming year, from ($2.92) to ($2.87) per share. Verve Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.Read More Verve Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/20/2024Estimated)------- 2/27/2024Q4 2023($0.83)($0.69)+$0.14($0.69)$3.95 million$5.14 million11/7/2023Q3 2023($0.90)($0.72)+$0.18($0.72)$0.96 million$3.10 million 8/10/2023Q2 2023($0.90)($0.87)+$0.03($0.87)$0.67 million$2.10 million5/15/2023Q1 2023($0.77)($0.84)($0.07)($0.84)$1.00 million$1.40 million3/2/2023Q4 2022($0.76)($0.67)+$0.09($0.67)$1.50 million$1.01 million11/7/2022Q3 2022($0.75)($0.79)($0.04)($0.79)$5.00 million$0.93 million Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2022Q2 2022($0.63)($0.84)($0.21)($0.84)--5/10/2022Q1 2022($0.63)($0.62)+$0.01($0.62)--3/14/2022Q4 2021($0.54)($0.65)($0.11)($0.65)--11/10/2021Q3 2021($0.45)($0.47)($0.02)($0.47)--8/12/2021Q2 2021($0.53)($2.13)($1.60)$2.40-- Verve Therapeutics Earnings - Frequently Asked Questions When is Verve Therapeutics's earnings date? Verve Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on VERV's earnings history. Did Verve Therapeutics beat their earnings estimates last quarter? In the previous quarter, Verve Therapeutics (NASDAQ:VERV) reported ($0.69) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.83) by $0.14. Learn more on analysts' earnings estimate vs. VERV's actual earnings. How much revenue does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded annual revenue of $11.76 million. How much profit does Verve Therapeutics generate each year? Verve Therapeutics (NASDAQ:VERV) has a recorded net income of -$200.07 million. VERV has generated -$3.12 earnings per share over the last four quarters. What is Verve Therapeutics's EPS forecast for next year? Verve Therapeutics's earnings are expected to grow from ($2.92) per share to ($2.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies: CureVac Earnings Mineralys Therapeutics Earnings Olema Pharmaceuticals Earnings Korro Bio Earnings Phathom Pharmaceuticals Earnings Astria Therapeutics Earnings Nuvation Bio Earnings Lyell Immunopharma Earnings GH Research Earnings AnaptysBio Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:VERV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
